Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRLD - US74065P1012 - Common Stock

2.66 USD
-0.1 (-3.62%)
Last: 1/9/2026, 3:29:41 PM
Fundamental Rating

2

PRLD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While PRLD seems to be doing ok healthwise, there are quite some concerns on its profitability. PRLD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRLD had negative earnings in the past year.
In the past year PRLD has reported a negative cash flow from operations.
PRLD had negative earnings in each of the past 5 years.
PRLD had a negative operating cash flow in each of the past 5 years.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of PRLD (-134.21%) is worse than 81.89% of its industry peers.
PRLD's Return On Equity of -217.26% is on the low side compared to the rest of the industry. PRLD is outperformed by 69.43% of its industry peers.
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRLD has been increased compared to 1 year ago.
PRLD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PRLD has a worse debt to assets ratio.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -11.26, we must say that PRLD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.26, PRLD is doing worse than 74.15% of the companies in the same industry.
There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.26
ROIC/WACCN/A
WACC8.83%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.21 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a worse Current ratio (3.21) than 61.70% of its industry peers.
A Quick Ratio of 3.21 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a Quick ratio (3.21) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 3.21
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.95% over the past year.
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%

3.2 Future

Based on estimates for the next years, PRLD will show a small growth in Earnings Per Share. The EPS will grow by 7.99% on average per year.
Based on estimates for the next years, PRLD will show a very strong growth in Revenue. The Revenue will grow by 103.00% on average per year.
EPS Next Y24.65%
EPS Next 2Y16.89%
EPS Next 3Y20.24%
EPS Next 5Y7.99%
Revenue Next Year-100%
Revenue Next 2Y400%
Revenue Next 3Y268.4%
Revenue Next 5Y103%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PRLD's earnings are expected to grow with 20.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.89%
EPS Next 3Y20.24%

More info and screens

0

5. Dividend

5.1 Amount

PRLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (1/9/2026, 3:29:41 PM)

2.66

-0.1 (-3.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners32.67%
Inst Owner Change0%
Ins Owners9.91%
Ins Owner Change0.18%
Market Cap167.23M
Revenue(TTM)7.00M
Net Income(TTM)-127.17M
Analysts84.44
Price Target4.08 (53.38%)
Short Float %3.75%
Short Ratio0.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.38%
Min EPS beat(2)8.54%
Max EPS beat(2)30.21%
EPS beat(4)4
Avg EPS beat(4)17.61%
Min EPS beat(4)8.54%
Max EPS beat(4)30.21%
EPS beat(8)7
Avg EPS beat(8)12.41%
EPS beat(12)11
Avg EPS beat(12)13.6%
EPS beat(16)14
Avg EPS beat(16)10.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)87.43%
EPS NY rev (1m)0%
EPS NY rev (3m)6.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.89
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.11
BVpS0.93
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.73%
Cap/Sales 1.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 3.21
Altman-Z -11.26
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
EPS Next Y24.65%
EPS Next 2Y16.89%
EPS Next 3Y20.24%
EPS Next 5Y7.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%
Revenue Next Year-100%
Revenue Next 2Y400%
Revenue Next 3Y268.4%
Revenue Next 5Y103%
EBIT growth 1Y-5.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.88%
OCF growth 3YN/A
OCF growth 5YN/A

PRELUDE THERAPEUTICS INC / PRLD FAQ

What is the fundamental rating for PRLD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRLD.


What is the valuation status for PRLD stock?

ChartMill assigns a valuation rating of 1 / 10 to PRELUDE THERAPEUTICS INC (PRLD). This can be considered as Overvalued.


What is the profitability of PRLD stock?

PRELUDE THERAPEUTICS INC (PRLD) has a profitability rating of 0 / 10.


How financially healthy is PRELUDE THERAPEUTICS INC?

The financial health rating of PRELUDE THERAPEUTICS INC (PRLD) is 5 / 10.